Huang Z, Cao J, Yao Y, Jin X, Luo Z, Xue Y, et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. Ann Transl Med. 2020;8:430.
Article
PubMed
PubMed Central
Google Scholar
Coronavirus disease (COVID-19) Situation report-121 highlights. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200520-covid-19-sitrep-121.pdf?sfvrsn=c4be2ec6_4. Accessed 9 Aug 2020
Feng Y, Ling Y, Bai T, et al. COVID-19 with different severity: a multi-center study of clinical features. 2020. https://doi.org/10.1164/rccm.202002-0445OC.
Wang Y, Roever L, Tse G, Liu T. 2019-novel coronavirus-related acute cardiac injury cannot be ignored. Curr Atheroscler Rep. 2020;22:14.
CAS
Article
PubMed
PubMed Central
Google Scholar
Kow CS, Zaidi STR, Hasan SS. Cardiovascular disease and use of renin-angiotensin system inhibitors in COVID-19. Am J Cardiovasc Drugs. 2020;20:217–221.
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:e102.
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811. https://doi.org/10.1001/jamacardio.2020.1017.
Article
PubMed
Google Scholar
Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5:825. https://doi.org/10.1001/jamacardio.2020.1624.
Article
PubMed
Google Scholar
Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012;49:1–15.
Article
Google Scholar
Zeng Z, Sha T, Zhang Y, Wu F, Hu H, Li H, et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study short title: hypertension in COVID-19 pneumonia patients. https://doi.org/10.1101/2020.04.06.20054825.
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:2582. https://doi.org/10.1056/NEJMoa2007621.NEJMc2021225.
Article
PubMed
Google Scholar
Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E004.
Google Scholar
Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. https://doi.org/10.1161/CIRCRESAHA.120.317134.
Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1855.
de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;6736:1–10.
Google Scholar
Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9:757–60.
CAS
Article
PubMed
PubMed Central
Google Scholar
Yang G, Tan Z, Zhou L, et al. Effects of ARBs and ACE is on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study. https://doi.org/10.1161/HYPERTENSIONAHA.120.15143.
Yan H, Valdes AM, Vijay A, et al. Role of drugs affecting the renin-angiotensin-aldosterone system on susceptibility and severity of COVID-19: a large case-control study from Zheijang Province, China. https://doi.org/10.1101/2020.04.24.20077875.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA - J Am Med Assoc. 2020;323:1239–42.
CAS
Article
Google Scholar
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323:2052. https://doi.org/10.1001/jama.2020.6775.
CAS
Article
PubMed
PubMed Central
Google Scholar
• Dauchet L, Lambert M, Gauthier V, et al. ACE inhibitors, AT1 receptor blockers and COVID-19: clinical epidemiology evidences for a continuation of treatments. The ACER-COVID study. medRxiv. https://doi.org/10.1101/2020.04.28.20078071. A recent study that suggested the risk and increased severity of COVID-19 infection was not associated with consumption of ACEi and ARB.
Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed 25 May 2020.
HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19 - American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. Accessed 3 May 2020.
ESH LETTER COVID-19 | European Society of Hypertension. https://www.eshonline.org/spotlights/esh-letter-covid-19-2/. Accessed 25 May 2020.
•• Guo X, Zhu Y, Hong Y RESEARCH LETTER Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis. https://doi.org/10.1161/HYPERTENSIONAHA.120.15572. A recent meta-analysis demonstrating decreased mortality of covid-19 with Renin Angiotensin-Aldosterone System Inhibitors Therapy in hypertensive patients.
Liu L, Qiu HB, Yang Y, Wang L, Ding HM, Li HP. Losartan, an antagonist of AT1 receptor for angiotensin II, attenuates lipopolysaccharide-induced acute lung injury in rat. Arch Biochem Biophys. 2009;481:131–6.
CAS
Article
PubMed
Google Scholar
Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441–2448.
Dahlöf B, Hansson L, Lindholm LH, Scherstén B, Wester PO, Ekbom T, et al. Stop-hypertension 2: a prospective intervention trial of “newer” versus “older” treatment alternatives in old patients with hypertension. Blood Press. 1993;2:136–41.
Article
PubMed
Google Scholar
Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the cooperative new Scandinavian Enalapril Survival Study II (Consensus II). N Engl J Med. 1992;327:678–84.
CAS
Article
PubMed
Google Scholar
Pflugfelder PW, Baird G, Tonkon MJ, DiBianco R, Pitt B, The Quinapril Heart Failure Trial Investigators. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawl in chronic heart failure: a double-blind, placebo-controlled study of quinapril. J Am Coll Cardiol. 1993;22:1557–63.
CAS
Article
PubMed
Google Scholar
Lee SM, Takemoto S, Wallace AW. Association between withholding angiotensin receptor blockers in the early postoperative period and 30-day mortality: a cohort study of the Veterans Affairs Healthcare system. Anesthesiology. 2015;123:288–306.
CAS
Article
PubMed
Google Scholar